Close

Clovis (CLVS) options active on FDA accepts rucaparib NDA for priority review

Go back to Clovis (CLVS) options active on FDA accepts rucaparib NDA for priority review

Clovis Oncology (CLVS) PT Raised to $19 at Credit Suisse as Priority Review/Label Are Best Case Scenario

August 24, 2016 7:34 AM EDT

Credit Suisse analyst K. MacKay reiterated a Neutral rating and raised its price target on Clovis Oncology (NASDAQ: CLVS) to $19.00 (from $14.00) announced the FDA has accepted its rucaparib NDA submission in 3L g/sBRCA+ ovarian cancer and has been granted priority review with a Feb 23, 2017 PDUFA date. The firm views the... More

Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval

August 24, 2016 6:34 AM EDT

Mizuho boosts its price taget on Neutral-rated Clovis Oncology (Nasdaq: CLVS) from $15 to $23 after the company announced that the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to... More

Stifel Affirms Clovis Oncology (CLVS) at 'Buy'; Sees Rucaparib Approval in Q117

August 24, 2016 6:14 AM EDT

Stifel affirms Clovis Oncology (Nasdaq: CLVS) with a Buy rating and $30 price target after the company announced that the U.S. Food and Drug Administration (FDA) has accepted... More